BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/16/2022 3:57:03 PM | Browse: 513 | Download: 1910
 |
Received |
|
2021-10-11 17:21 |
|
Peer-Review Started |
|
2021-10-11 17:23 |
|
First Decision by Editorial Office Director |
|
2021-12-03 21:32 |
|
Return for Revision |
|
2021-12-06 06:05 |
|
Revised |
|
2021-12-14 16:30 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2022-02-15 03:19 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2022-02-16 07:27 |
|
Articles in Press |
|
2022-02-16 07:27 |
|
Edit the Manuscript by Language Editor |
|
2022-02-11 21:31 |
|
Typeset the Manuscript |
|
2022-03-10 16:40 |
|
Publish the Manuscript Online |
|
2022-03-16 15:57 |
| ISSN |
1948-5190 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Observational Study |
| Article Title |
SARS-CoV-2 in inflammatory bowel disease population: Antibodies, disease and correlation with therapy
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Clara Benedetta Conti, Elsa Mainardi, Sara Soro, Sophie Testa, Annalisa De Silvestri, Andrea Drago, Fabrizio Cereatti and Roberto Grassia |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Clara Benedetta Conti, MD, Consultant Physician-Scientist, Gastroenterology and Digestive Endoscopy, ASST Cremona, Viale Concordia 1, Cremona 26100, Italy. benedetta.conti1@gmail.com |
| Key Words |
Inflammatory bowel disease; SARS-CoV-2; COVID-19; Biologic treatment; SARS-CoV-2 antibody; Inflammatory bowel disease therapy |
| Core Tip |
Guidelines recommend ceasing inflammatory bowel disease (IBD) biologic therapy during coronavirus disease 2019 (COVID-19). IBD patients were prospectively tested for severe acute respiratory syndrome coronavirus 2 IgG. In total, 103 IBD patients were enrolled. We found that 18.4% had IgG positivity, and 63% developed COVID-19 disease with symptoms. However, all but one patient with symptoms did not require ceasing IBD treatment no hospitalization. None of the patients under biologic therapy developed severe COVID-19. Therefore, the IBD population does not seem to have a high risk of severe COVID-19, particularly if under biological treatment or mesalazine. |
| Publish Date |
2022-03-16 15:57 |
| Citation |
Conti CB, Mainardi E, Soro S, Testa S, De Silvestri A, Drago A, Cereatti F, Grassia R. SARS-CoV-2 in inflammatory bowel diseases population: Antibodies, disease and correlation with therapy. World J Gastrointest Endosc 2022; 14(3): 153-162 |
| URL |
https://www.wjgnet.com/1948-5190/full/v14/i3/153.htm |
| DOI |
https://dx.doi.org/10.4253/wjge.v14.i3.153 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
